Drug price negotiation for lung cancer treatment ‘Tagrisso’ failed
The drug price negotiation of ‘Tagrisso,’ a new lung cancer drug of AstraZeneca, a multinational pharmaceutical company, was delayed for a week due to the Ministry of Health and Welfare’s order to suspend negotiation, which has attracted attention of the industry.
According to the pharmaceutical...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
